In many tumor cell types, ionizing radiation or DNA-damaging anticancer drugs enhance sensitivity to death receptor-mediated apoptosis, which is of clinical interest. APO010, a form of CD95/Fas ligand is currently in a phase I trial in patients with solid tumors. To analyze the potential of combined modality treatment with APO010, we used p53-mutant Jurkat T leukemic cells, in which the mitochondrial pathway was blocked by Bcl-2 overexpression. These cells were strongly sensitized to APO010 by pretreatment with ionizing -or UV radiation, etoposide, histone deacetylase -or proteasome inhibitors. These stimuli alone did not induce apoptosis in J16-Bcl-2 cells. Sensitization could not be explained by the overruling of mitochondrial resistance imposed by Bcl-2, upregulation of CD95 membrane levels or modulation of inhibitor of apoptosis proteins. Rather, the stimuli commonly downregulated c-FLIP L/S protein levels, which was causally related to the sensitization: deliberate c-FLIP L/S downregulation by RNA interference largely overruled the capacity of the various stimuli to sensitize Jurkat-Bcl-2 cells to apoptotic execution by APO010. In p53-mutant, Bcl-2 overexpressing HCT-15 colon carcinoma cells, c-FLIP downregulation correlated with sensitization to APO010 for some, but not all stimuli. We conclude that c-FLIP downregulation represents a mechanism by which diverse anticancer regimens can facilitate tumor cell execution by CD95/Fas through the direct pathway of caspase activation.
Inhibition of apoptotic pathways critically contributes to cancer development. Consequently, tumor cells are often 'addicted' to overexpression of anti-apoptotic proteins, such as Bcl-2, for their survival. Targeting apoptosis regulators in cancer treatment is therefore interesting, as overcoming blocks in apoptosis may render cancer cells more susceptible to death than normal cells. 1 Ionizing radiation (IR) and DNA-damaging chemotherapeutics are effective in cancer treatment, because they hamper clonogenicity of tumor cells in a variety of ways. The DNA damage that they induce triggers an often p53-dependent cell cycle arrest allowing for DNA repair. Failing this, irreversible cell cycle arrest, death due to mitotic catastrophe or apoptotic cell death may ensue. 2 Apoptosis induction by DNA-damaging anticancer regimens is blocked by Bcl-2 overexpression, indicating that apoptosis signalling proceeds through the intrinsic, mitochondrial pathway. 3 In this pathway, pro-apoptotic members of the Bcl-2 family induce mitochondrial permeabilization, and the subsequent release of cytochrome c (Cyt c) and other mediators allows for Caspase-9 and effector caspase activation. 4 In hematopoietic tumors, the apoptotic response to IR and DNA-damaging drugs is generally evident, and apoptosis resistance can contribute to treatment resistance. 5 Solid tumors are less apoptosis prone when treated with conventional regimens. Therefore, the death receptor ligand TRAIL was of immediate clinical interest when it effectively induced apoptosis in many long-term established solid tumor cell lines. TRAIL proved non-toxic to normal tissue in animal models and moved rapidly toward the clinical testing phase. 6 Currently, TRAIL receptor agonists are in phases I and II clinical trials, either as single modality treatment or in combination with conventional or novel anticancer drugs. 7 Combined modality treatment with death receptor agonists and DNA-damaging anticancer regimens was expected to be more effective than single-agent treatment, given the distinct cell death pathways they engage. TRAIL-R1/2 and CD95 death receptors induce apoptosis by directly recruiting and activating caspases. 8 Upon ligand binding, they recruit FADD, inducer caspase-8 and/or caspase-10 and c-FLIP molecules. 8, 9 In the death-inducing signalling complex (DISC) thus formed at the cytoplasmic receptor tail, caspase-8/10 are activated. Depending on their expression level, c-FLIP molecules can facilitate or inhibit this activation. 10 Upon selfprocessing by proteolysis, caspase-8/10 are released into the cytosol, in which they find effector caspases as their targets. In this way, death receptors can in principle execute apoptosis in a mitochondrion-independent manner. However, by cleaving and activating BH3-only protein, Bid, caspase-8/10 also connect death receptors to the mitochondrial pathway. 4 The efficacy of TRAIL receptors and CD95 to kill cells through the direct pathway for effector caspase activation depends on the cell type. In the so-called type II cells, the mitochondrial contribution is required for apoptotic execution, whereas in type I cells it is not, as ascertained by Bcl-2 overexpression. This relates to the efficacy of caspase-8/10 activation in the DISC, which seems a cell-intrinsic phenomenon. 11 The mitochondrial bypass by death receptors is of interest, as it potentially overrules intrinsic apoptosis resistance in tumor cells, as for example, imposed by Bcl-2 overexpression.
Although TRAIL receptors and CD95/Fas induce apoptosis by highly similar mechanisms, 8, 9 CD95 agonists were not pursued for cancer therapy, because of severe hepatotoxicity upon systemic administration in mice. 12 Recently however, a phase I clinical trial has been initiated at TopoTarget (ClinicalTrials.gov identifier: NCT00437736) with APO010 (MegaFas Ligand). This is a fusion protein of the extracellular domain of CD95L/FasL and the collagen domain of the serum protein ACRP30. The dimer of CD95L trimers that is thus formed can crosslink two adjacent CD95 trimers, rendering APO010 highly agonistic as compared with other available CD95 agonists. 13 It is therefore envisioned that a combined modality treatment with low concentrations of this agent is effective and has acceptable toxicity, especially in settings of local therapy, such as radiotherapy or local perfusion with anticancer drugs. We have recently shown that in p53-mutant Jurkat cells engineered to overexpress Bcl-2 (J16-Bcl-2), as well as in solid tumor types, APO010 and IR had a combined effect on cell death induction, both in short-term apoptosis assays and in clonogenic survival assays. 14 In this study we show that pre-treatment with not only IR, but also with UV radiation and various anticancer drugs sensitizes J16-Bcl-2 cells to APO010-mediated apoptosis, without breaking mitochondrial resistance imposed by Bcl-2 or upregulating CD95 membrane levels. The underlying mechanism concerns downregulation of c-FLIP long (L) and short (S) isoforms, which enables apoptotic execution by CD95 through the direct pathway for caspase activation. As Jurkat cells are classified as type II cells, 15 this implies a conversion from type II to type I signalling by CD95.
Results
Combining APO010 with chemotherapy overcomes apoptosis resistance imposed by Bcl-2. The wild-type Jurkat clone J16 readily undergoes apoptosis upon single treatment with the death ligands, CD95/FasL or TRAIL, or with the DNA-damaging anticancer regimens, IR or etoposide. 16 The response of J16 cells to each of these stimuli was strongly impaired upon Bcl-2 overexpression. 14, 16 J16-Bcl-2 cells therefore provided an excellent cellular system to examine whether combined treatment with APO010 and anticancer regimens might overrule resistance imposed by Bcl-2. APO010 and IR were previously shown to have a combined effect on the apoptotic response of J16-Bcl-2 cells.
14 To analyze whether this also held true for DNAdamaging drugs, we examined the combined effects of APO010 and etoposide, which is a topoisomerase inhibitor that -similar to IR -induces double-strand DNA breaks. The cells were stimulated with different doses of APO010 in the presence or absence of etoposide and apoptosis was read out after 48 h by nuclear fragmentation. J16-Bcl-2 cells were fully resistant to treatment with 2 mg/ml etoposide alone ( Figure 1a) . As expected from the type II nature of Jurkat cells, 15 J16-Bcl-2 cells also showed low sensitivity to APO010 alone. In agreement with our previous work 16 and studies by others, 17, 18 Bcl-2 overexpression did not fully abrogate the apoptotic response of J16 cells to CD95 stimulation, as evident at high doses of APO010 (Figure 1a) . Upon combined treatment with etoposide, however, J16-Bcl-2 cells were significantly more sensitive to APO010 and underwent apoptosis at very low doses ( Figure 1a ). Wild-type J16 cells were highly sensitive to treatment with 2 mg/ml etoposide alone, which precluded a read out for sensitization to APO010 (Supplementary Figure 1) . To analyze whether etoposide pre-conditioned J16-Bcl-2 cells to more efficiently activate effector caspases upon APO010 stimulation, the cells were first incubated with etoposide and 15 h later stimulated with APO010. Whereas APO010 alone readily induced caspase-3 activation in parental J16 cells, J16-Bcl-2 cells were relatively resistant. In etoposide-pretreated J16-Bcl-2 cells, caspase-3 activation upon APO010 treatment was significantly enhanced, approximating the response observed in J16 cells by APO010 treatment alone (Figure 1b ). Caspase-3 activation correlated with the cell death response as measured by nuclear fragmentation and propidium iodide (PI) uptake (Supplementary Figure 2) .
As effector caspases are directly activated by caspase-8/10 in the mitochondrion-independent death receptor pathway, we analyzed whether pre-treatment with etoposide improved the capacity of APO010 to activate caspase-8. In etoposidetreated J16-Bcl-2 cells, caspase-8 activation -as read out by appearance of the p41/p43 and p18 cleavage products -was first observed at 2 h after APO010 stimulation (Figure 1c ). Caspase-3 activity was also apparent by proteolytic processing of its substrate PARP. At each subsequent time point, caspase-8 activation and PARP processing were more pronounced in cells incubated with etoposide than in untreated cells.
We conclude that etoposide treatment conditioned J16-Bcl-2 cells to more efficiently activate inducer and effector caspases upon APO010 stimulation.
Mitochondrial resistance imposed by Bcl-2 is not broken upon combined treatment. It was possible that in etoposide-treated cells, APO010 evoked effector caspase activation by overruling the mitochondrial resistance imposed by Bcl-2. Therefore, we monitored Cyt c release in parental J16 cells and in J16-Bcl-2 cells that were pretreated with etoposide or not. J16 cells showed Cyt c release upon APO010 treatment but J16-Bcl-2 cells did not, throughout the 8-h time course, showing the effectiveness of Bcl-2 in preventing mitochondrial permeabilization (Figure 2a) . The primary data depicted in Figure 2b illustrate this point.
Type II to type I switch by anticancer drugs in Jurkat cells I Verbrugge et al Importantly, J16-Bcl-2 cells that were pretreated with etoposide showed no significant increase in Cyt c release after APO010 stimulation, even after 8 h (Figure 2b ). These were the same samples analyzed for caspase-3 activation in Figure 1b , indicating that effector caspase activation in etoposide-treated J16-Bcl-2 cells was not a consequence of breaking Bcl-2-mediated mitochondrial resistance. We conclude that after etoposide treatment, APO010 more efficiently activated effector caspases through the direct, mitochondrion-independent pathway.
Etoposide downregulates c-FLIP L/S and improves caspase-8 activation in the DISC. As caspase-8 is activated in the DISC, we analyzed whether DISC formation was improved in etoposide-treated cells. After 15 h of incubation in the presence or absence of etoposide, J16-Bcl-2 cells were stimulated with crosslinked CD95L. The combined treatment effect in this setting was verified using enhanced PARP processing in corresponding total cell lysates ( Figure 3a) . The DISCs isolated from etoposide pretreated cells showed enhanced caspase-8 activation as compared to the DISCs from control cells, which was most apparent at the 4-h time point (Figure 3a ). In the same samples, the DISCs from etoposide-treated cells showed a decrease in processed c-FLIP L levels. Immunoblotting of total cellular lysates of control and etoposide-treated cells for c-FLIP levels showed that etoposide treatment reduced protein expression of the FLIP L and FLIP S isoforms (Figure 3b ). This was a posttranslational effect, as c-FLIP mRNA levels were not reduced after etoposide treatment (Supplementary Figure 3) .
These results suggest that downregulation of c-FLIP protein levels by etoposide treatment enhanced the ability of CD95L to activate caspase-8 in the DISC.
JNK inhibition reveals the relation between c-FLIP downregulation and sensitization to APO010. It was . After 15 h (t ¼ 0), the cells were stimulated with 0.4 ng/ml APO010 and harvested at the indicated time points. After separation by SDS-PAGE, protein levels of the p53/55 caspase-8 proform and its p41/43 and p18 cleavage products and the PARP p116 proform and its p85 cleavage product were determined using immunoblotting. Actin served as a loading control. The numbers indicate integrated density values of the caspase-8 p41/43, caspase-8 p18 and PARP p85 fragments, as quantified from autoradiograms and normalized to Actin signals in arbitrary units shown previously that activation of the Jun N-terminal kinase (JNK) pathway through activation of the E3 ubiquitin ligase Itch leads to c-FLIP downregulation. 19 As etoposide is known to activate the JNK pathway, for example, 20 we tested whether JNK inhibition -using the chemical inhibitor SP600125 21 or the cell permeable L-JNKi peptide Figure 4) .
These results indicate that in J16-Bcl-2 cells, etoposidemediated activation of the JNK pathway is (partly) responsible for c-FLIP downregulation. Moreover, they suggest that c-FLIP downregulation by etoposide is causally related to the drug's ability to sensitize J16-Bcl-2 cells to APO010-induced apoptosis.
Downregulation of c-FLIP by RNA interference sensitizes J16-Bcl-2 cells to APO010. To test whether c-FLIP downregulation was sufficient to sensitize J16-Bcl-2 cells to APO010-induced apoptosis, we stably downregulated c-FLIP levels in these cells by RNA interference (RNAi), using retroviral constructs. The different short interfering (si) RNA constructs tested downregulated c-FLIP isoforms to a variable degree. The FLIP1 construct strongly reduced the expression of c-FLIP L and FLIP S , whereas for example, the FLIP4 construct had a clear, but more modest effect (Figure 5a ).
Upon treatment of FLIP1 and FLIP4 cell lines with APO010, caspase-3 activation was enhanced as compared with empty We next analyzed to which extent etoposide treatment could (further) sensitize control, FLIP1-or FLIP4-transduced J16-Bcl-2 cells to APO010-induced apoptosis. After pretreatment with etoposide, cells were stimulated for 8 h with APO010. Control cells were efficiently sensitized to APO010 by etoposide in a dose-dependent manner. FLIP1-transduced cells were very sensitive to treatment with APO010 alone, and etoposide treatment incremented the response to a limited degree. FLIP4-transduced cells were sensitized to a lesser extent by c-FLIP siRNA, allowing us to quantify the added effect of etoposide pretreatment (Figure 5d ). For this purpose, caspase-3 activation upon combined treatment was normalized to caspase-3 activation by APO010 alone and expressed as fold sensitization. This analysis revealed that etoposidemediated sensitization to APO010 in FLIP4-transduced cells was significantly reduced as compared with control cells (Figure 5d ).
In summary, c-FLIP downregulation by RNAi greatly facilitated the mitochondrion-independent pathway for effector caspase activation and largely overruled the capability of etoposide to increment apoptotic execution. These data indicate that downregulation of c-FLIP protein expression is a major mechanism by which etoposide sensitizes J16-Bcl-2 cells to APO010-induced apoptosis.
Various stimuli that sensitize J16-Bcl-2 cells to APO010 downregulate c-FLIP. Next, we examined whether other stress stimuli could also facilitate APO010-induced apoptosis in J16-Bcl-2 cells. For this purpose, cells were pre-treated with IR, UV radiation, the HDAC inhibitors, trichostatin A (TSA) and valproic acid (VPA), or the proteasome inhibitors, MG132 and lactacystin. In all cases, pretreatment significantly enhanced APO010-induced apoptosis (Figures  6a-d) . In the time frame of pre-sensitization, IR slightly increased CD95 membrane levels (Figure 6f ), but etoposide and UV had no effect, whereas VPA and TSA significantly . After 15 h, the cells were stimulated with 20 ng/ml FLAG-CD95L pre-coupled to 100 ng/ml biotinylated anti-FLAG antibody for the indicated periods of time. CD95L-bound receptor complexes were isolated using streptavidin-conjugated sepharose beads. Caspase-8 and c-FLIP in the CD95L DISC were detected using immunoblotting. The caspase-8 proforms (p53/55) and their cleavage products (p41/43, p18), as well as the c-FLIP L proform (p53) and its cleavage product (p41) are indicated. The combined effects in this setting were confirmed using immunoblotting, corresponding cell lysates for PARP processing (conversion of p116 to p85) as a measure for effector caspase activity. Actin served as a loading control. (b) Protein levels of c-FLIP L/S in total lysates of J16-Bcl-2 cells were detected using immunoblotting at 15 h after incubation in the absence (Control) or presence of 2 mg/ml etoposide (Etop). Actin served as a loading control downregulated CD95. This ruled out CD95 upregulation at the plasma membrane as the mechanism for increased APO010 sensitivity.
In addition, we found no evidence that the modulation of inhibitor of apoptosis protein (IAP) expression was instrumental in the sensitization to APO010-induced apoptosis. First, treatment with etoposide or IR did not alter c-IAP-1, c-IAP-2 or XIAP mRNA or protein expression in J16 cells. 16 Second, stable expression of a validated cytosolic SMAC mutant (J16-Bcl-2-D55 SMAC) 16 did not abrogate the capacity of etoposide to sensitize J16-Bcl-2 cells to APO010-induced apoptosis (Supplementary Figure 5) .
The treatment of J16-Bcl-2 cells with each of the stimuli did, however, downregulate total cellular c-FLIP protein levels (Figure 6e ). In the case of IR, UV and VPA, SP600125 could not overrule sensitization (Supplementary Figure 6) , which correlated with an inability to restore c-FLIP levels (Supplementary Figure 7 and data not shown).
We conclude that in addition to etoposide, IR, UV radiation, HDAC and proteasome inhibitors also sensitized J16-Bcl-2 cells to APO010 apoptosis, which was correlated with c-FLIP downregulation.
Downregulation of c-FLIP by RNAi impairs the ability of different stimuli to sensitize to APO010. Subsequently, we used c-FLIP RNAi to test whether c-FLIP downregulation was a common mechanism by which the various stress stimuli sensitized J16-Bcl-2 cells to APO010-induced Figure 8c) . IR yielded a very low level of sensitization of HCT-15-Bcl-2 cells to APO010-induced apoptosis (P ¼ 0.015 at t ¼ 8 h) and did not measurably downregulate c-FLIP protein levels. Therefore, in these cases, a correlation between sensitization to APO010 and c-FLIP downregulation was apparent. Etoposide, however, sensitized HCT-15-Bcl-2 cells to APO010-induced apoptosis at intermediate levels (P ¼ 0.001 at t ¼ 8 h; Supplementary Figure 8a ), yet did not detectably downregulate c-FLIP protein levels (Supplementary Figure 8c) . Sensitization to any of these stimuli was not correlated with downregulation of XIAP, cIAP1 or cIAP2 protein levels (Supplementary Figure 8d) .
These results indicate that c-FLIP downregulation may contribute to, but is not the only mechanism, by which type II tumor cells can be sensitized to APO010-induced apoptosis.
Discussion
Many reports describe the combined effects of conventional or targeted anticancer regimens and death receptor agonists in tumor cell killing. For TRAIL receptor agonists in particular, combination treatment proved effective in a variety of tumor types in vitro and in vivo. 6 The mechanisms of the action of death receptors and conventional anticancer regimens predict additivity in combined treatment. Moreover, upregulation of death receptors at the plasma membrane in response to DNAdamaging regimens may lead to synergy, in particular in p53-proficient cells. 6 However, in various cell lines, such as Jurkat leukemia, 16 HT-29 colon carcinoma 25 and Hep3b hepatocellular carcinoma, 26 the combined effects of TRAIL and DNAdamaging regimens could not be explained by changes in receptor membrane expression, raising the question of the underlying molecular mechanism.
In this study we show that pretreatment with not only conventional anticancer regimens, such as IR and etoposide, but also UV radiation, HDAC inhibitors and proteasome inhibitors sensitized J16-Bcl-2 cells to APO010-induced apoptosis, in the absence of CD95 upregulation and without breaking mitochondrial resistance. In the time frame in which caspase-3 activation was observed -as read out by occurrence of its cleaved form and cleavage of its substrate PARP -Cyt c release did not take place. In agreement with this, we previously found that downregulation of Bak and Bax by RNAi in J16-Bcl-2 cells did not alter the combined response to IR and TRAIL. 16 Sensitization resulted in improved caspase-8 activation by CD95 and execution through the direct pathway for effector caspase activation, which could be explained by c-FLIP downregulation.
Most likely, the reduction in c-FLIP protein levels induced by the different stimuli examined in this study allowed fewer c-FLIP molecules to be recruited into the CD95L DISC, thereby altering the c-FLIP/caspase-8/10 ratio. c-FLIP has a dual role in the DISC, as it inhibits caspase-8/10 activation when present at high levels, but can promote caspase-8/10 activation when present at low levels. 10 We found that c-FLIP downregulation facilitated caspase-8/10 activation in the CD95L DISC. This agrees with other studies: in SHEP neuroblastoma cells, cycloheximide or actinomycin D treatment reduced cellular c-FLIP protein levels and participation in the CD95L-DISC and incremented inducer caspase activation. 27 Prostate carcinoma 28 and Hodgkin/Reed-Sternberg cells 29 were sensitized to CD95-mediated apoptosis by c-FLIP RNAi. Moreover, melanoma cells were sensitized to both CD95-and TRAIL-receptor-induced apoptosis by c-FLIP RNAi. 30 On the basis of current data, downregulation of c-FLIP -which is overexpressed in several tumor types -was recently proposed as a rational strategy to sensitize tumor cells to death ligand therapy. 31 Future studies should pinpoint whether downregulation of the long or short isoform of c-FLIP is the critical determinant in sensitizing Jurkat-Bcl-2 cells to APO010-induced apoptosis. Both isoforms can be recruited to the DISC. 32 Downregulation of c-FLIP L was most consistently observed, but c-FLIP S levels were also affected. To resolve this issue, an isoform-specific RNAi approach is required. We previously found that pre-treatment of J16-Bcl-2 cells with IR improved effector caspase-8/10 activation in the DISC and thereby allowed cellular execution by TRAIL through the direct pathway for effector caspase activation. 16 In this study we show that in the same cells, c-FLIP downregulation by various stress stimuli allowed APO010 to bypass the mitochondrial pathway for apoptotic execution. These findings imply that the stress stimuli promote a 'switch' from type II to type I death receptor signalling in J16-Bcl-2 cells. In addition, in type II CEM leukemia cells, cycloheximide pretreatment allowed CD95-mediated apoptosis through the direct pathway. 33 It is important to determine the generality of the mechanism defined in this study for J16-Bcl-2 cells and, in particular, whether it operates in solid tumors also. We have examined the case of HCT-15 colon carcinoma cells, as these have been well defined in terms of p53 mutant and type II status. UV and VPA could sensitize these cells to APO010-induced apoptosis, but IR was less effective. With these stimuli, a correlation between c-FLIP downregulation and sensitization to APO010-induced apoptosis was found. However, the correlation was not evident in the case of etoposide, which sensitized HCT-15-Bcl-2 cells to APO010 in the absence of c-FLIP downregulation. In SHEP neuroblastoma cells overexpressing Bcl-2, 27 we found a correlation between FLIP downregulation and sensitization by UV, but not with the other stimuli (data not shown). Therefore, cells may be sensitized by other mechanisms to undergo an apparent type II to type I switch. In addition, in other type II cells (mesothelioma and carcinoma cell lines), an intact mitochondrial amplification loop was required for apoptotic execution upon combined treatment with DNA-damaging regimens and TRAIL, even though inducer caspase activity was enhanced. [34] [35] [36] Therefore, enhanced inducer caspase activation may be sufficient in some cell types for execution through the direct pathway, whereas in other cell types -perhaps particularly in solid tumors -the mitochondrial pathway may still be required.
Concerning sensitization to TRAIL-induced apoptosis, a number of studies report a correlation between c-FLIP downregulation by cellular stressors and increased sensitivity to apoptosis. 31 In colon 25 and hepatocellular 26 carcinoma, c-FLIP downregulation by 5-FU was correlated with reduced levels of c-FLIP in the TRAIL DISC and with enhanced sensitivity to TRAIL-mediated apoptosis. However, we found that 10 Gy IR did not detectably alter c-FLIP levels in J16-Bcl-2 cells and did not sensitize them to APO010-induced apoptosis (data not shown), whereas it did improve TRAIL DISC activity and apoptosis induction. 16 This suggests that CD95 and TRAIL receptors have partially distinct requirements to activate inducer caspases in the DISC.
In J16-Bcl-2 cells, IR, UV radiation, etoposide, HDAC and proteasome inhibitors all downregulated c-FLIP protein levels. c-FLIP expression is tightly controlled, both at the transcriptional and at the protein level. The NF-kB pathway can induce c-FLIP transcription, although the ubiquitin-proteasome pathway mediates c-FLIP degradation. 37, 38 c-FLIP molecules have a short half-life and are subject to proteasomal degradation at the steady state. In addition, they are ubiquitinated in response to death receptor stimulation, through a defined ubiquitin ligase that is under the control of the JNK pathway. 19, 38 In agreement with this, short-term incubation with proteasome inhibitor rescued the disappearance of c-FLIP after addition of the stress stimuli, but upon prolonged incubation, c-FLIP was still downregulated (results not shown). This can be explained by the fact that proteasome activity is required for NF-kB activation, which in turn directs c-FLIP transcription.
In case of etoposide, we found that JNK inhibition impeded c-FLIP downregulation. This concurs with the report that implicated JNK in c-FLIP ubiquitination 19 and with the finding that JNK inhibition reversed etoposide-mediated sensitization to TRAIL in mesothelioma cells. 20 In case of UV radiation, however, which potently activated the JNK pathway and downregulated c-FLIP, the JNK inhibitors -although functional -could not rescue c-FLIP protein expression. Only in case of IR, c-FLIP levels were partially restored upon JNK inhibition (Supplementary Figure 7) . The extent of c-FLIP restoration correlated with the extent to which sensitization to APO010 was reversed (Supplementary Figure 6) . Therefore, JNK activation may contribute to, but is not a general mechanism by which c-FLIP is downregulated in response to stress stimuli, and JNK activation per se does not sensitize cells for APO010-induced apoptosis.
In conclusion, c-FLIP downregulation is a common mechanism by which various stress inputs sensitize J16-Bcl-2 cells to CD95-mediated apoptosis through the direct pathway for caspase activation. The apparent ability of death receptors to 'switch' from type II to type I signalling after c-FLIP downregulation may be of more general relevance for sensitizing tumor cells to death receptor-mediated apoptosis. It will be of interest to determine in which primary tumor types this is the case.
Materials and Methods
Cell lines and reagents. The J16 Jurkat clone stably overexpressing Bcl-2 and luciferase (J16-Bcl-2) was generated by retroviral transduction as described.
39
J16 cells are heterozygous mutant for p53 and the DNA damage-induced apoptosis pathway is p53 independent.
39 J16-Bcl-2 cells and derivatives were cultured in Iscove's modified Dulbecco's medium with 8% fetal bovine serum and antibiotics. APO010 in native and biotinylated form was kindly provided by TopoTarget (Lausanne, Switzerland), produced as described 14 and kept frozen in storage buffer at À801C. SP600125 was from ENZO Life Sciences International Inc. (Zandhoven, Belgium).The cell permeable L-JNKi peptide (sequence NGRKKRRQRRRPPR PKRPTTLNLFPQVPRSQD with carboxy-terminal amide) was produced at the Division of Cell Biology at the Netherlands Cancer Institute, according to the standard procedures. The product was purified by HPLC and its sequence was verified using mass spectrometry. TSA, VPA, anti-caspase-8 monoclonal antibody (mAb, clone C15), anti-FLIP mAb (clone NF6) and soluble human FLAG-tagged CD95L were obtained from Alexis Biochemicals (Lausanne, Switzerland). Biotinylated anti-FLAG mAb (clone M2), etoposide, puromycin and blasticidin S were from Sigma-Aldrich (St. Louis, MO, USA). Anti-Cyt c mAb (clone 6H2.B4), anti-XIAP mAb and rabbit antiactive caspase-3 antibody were from BD Biosciences (San Jose, CA, USA), anti-actin mAb (clone C4) was from Chemicon International (Temecula, CA, USA) and rabbit anti-cIAP1 and anti-cIAP2 were from R&D Systems (Abingdon, UK). AlexaFluor 647-conjugated goat anti-mouse Ig and goat anti-rabbit Ig were from Molecular Probes (Leiden, The Netherlands). Lactacystin and MG132 were from Calbiochem (Darmstadt, Germany). Horseradish peroxidase-conjugated rabbit anti-mouse Ig and swine anti-rabbit Ig were from DAKO A/S (Glostrup, Denmark) and the enhanced chemiluminescence kit was from Pierce Biotechnology (Rockford, IL, USA). Rabbit anti-PARP polyclonal Ab (pAb) 9542 was from Cell Signaling Technologies (Danvers, MA, USA). Streptavidin-conjugated sepharose beads were from Zymed (San Francisco, CA, USA). 0 -GCAAGGAGAAGAGTTTCTT-3 0 ) was performed with the pRSC retroviral vector, which is a modification of pRetroSuper 40 with a puromycin resistance cassette. Packaging of the (dideoxynucleotide sequence verified) constructs in the HT1080 packaging cell line FLY and transduction of J16-Bcl-2 cells with freshly harvested virus supernatant was carried out as described. 16 Cells were selected after 3 days with 1 mg/ml puromycin.
Apoptosis assays. For apoptosis assays, cells were stimulated with the indicated doses of APO010, etoposide, IR, TSA, VPA, MG132 or lactacystin in their normal medium. After addition of stimulus, cells were incubated for the indicated time periods at 37 1C in 5% CO 2 . IR was delivered using a 137 Cs source (415 Ci; Von Gahlen Nederland, B.V., Zevenaar, The Netherlands) at an absorbed dose rate of approximately 0.6 Gy/min. For UV irradiation, 5 Â 10 5 cells were resuspended in 500 ml culture medium and transferred into 12-well plate. After allowing cells to sink to the bottom of the plate for at least 30 min, UV irradiation was performed using the UV Stratalinker 2400 (Stratagene, La Jolla, CA, USA) at a dose rate of 10 J/m 2 /s. In some experiments, cells were incubated (before sensitization) with 10 mM SP600125 for 30 min or 10 mM L-JNKi peptide for 24 h at 37 1C in 5% CO 2 . Nuclear fragmentation was determined using flow cytometric analysis of PI-stained nuclei as described. 16 Data were analyzed using FCS Express (De Novo Software, Thornhill, Canada). Cellular debris was excluded from analyses and the percentage of subdiploid PI-positive particles was scored as percentage apoptosis. Active caspase-3 content and Cyt c release using flow cytometry were determined as described. 16 DISC isolation. J16-Bcl-2 cells were stimulated with 2 mg/ml etoposide and 15 h later seeded at 10 8 cells/sample in 30 ml medium in a 15-cm dish. Cells were stimulated with 20 ng/ml FLAG-CD95L pre-coupled to 100 ng/ml biotinylated anti-FLAG M2 mAb for the indicated periods of time. DISC isolation was performed as described, 16 with some modifications of the original protocol. Immunoblotting. Total cellular protein was determined using Bio-Rad protein assay (München, Germany) and was separated at 40 mg per lane on 4-12% NuPage Bis-Tris gradient gels (Invitrogen, Breda, The Netherlands) in MES buffer, according to the manufacturer's instructions. Subsequent immunoblotting was performed as described in Verbrugge et al. 16 and the references in that study. For some blots, the iBlot system (Invitrogen) was used according to the manufacturer's instructions. Where appropriate, autoradiography signals were quantified using a Fluorchem8000 chemiluminescence imager (Alpha Innotech Corp., San Leandro, CA, USA).
Flow cytometric detection of CD95. For flow cytometric detection of CD95 surface levels, cells were incubated for 15 h with the indicated stimuli at 37 1C in 5% CO 2 . After incubation, cells were stained with biotinylated APO010 and subsequently with streptavidin-conjugated allophycocyanine (BD Pharmingen, San Diego, CA, USA). Samples were gated on live, PI-negative cells and data were analyzed using FCS Express. Mean fluorescence intensity values of stimulated cells were normalized to those of unstimulated (Control) cells.
Statistics. The differences between treatment groups were analyzed using unpaired Student's t-tests and were considered significant when Po0.05. The analyses were performed using GraphPad Prism version 4 for Windows (Graph Pad Software, San Diego, CA, USA).
